May 16, 2018
- FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings (Update)
- Drug Approval Packages:
- Drug Firm Annual Registration Status (updated)
- Drug Firm Annual Registration Status Download File (updated)
- National Drug Code Directory (updated)
- Wholesale Distributor and Third-Party Logistics Providers Reporting (updated)
- FDA reports quality problems for data provided by the firm IQVIA that were used to inform estimates for some controlled substances
.png)
No hay comentarios:
Publicar un comentario